ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "diagnosis and systemic lupus erythematosus (SLE)"

  • Abstract Number: 1690 • 2018 ACR/ARHP Annual Meeting

    Increased Sensitivity Οf Τhe New (2017) Αnd Τhe 2012 SLICC As Compared Τo Τhe Acr 1997 Classification Criteria Ιn Early Systemic Lupus Erythematosus (SLE): The 2017 Αnd 2012 Criteria May Classify Non-Overlapping Subgroups Οf Patients

    Christina Adamichou1, Dionysios Nikolopoulos2, Alessandra Bortoluzzi3, Emmanouil Papastefanakis1, Antonis Fanouriakis2, Eleni Kalogiannaki1, Irini Gergianaki1, Prodromos Sidiropoulos1 and George Bertsias1, 1Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, 24th Department of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece, 3Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy

    Background/Purpose: SLE diagnosis can be challenging especially at the early stages, and existing classification criteria are biased towards classifying patients with long-standing disease. A joined…
  • Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting

    Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients

    Katalin Banki1, Phillip Aleksiejuk2, Jessica Patel2 and Andras Perl3, 1Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, 2Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, 3Department of Medicine, Upstate Medical University, Syracuse, NY

    Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss.  Although several tests exist to guide diagnosis of…
  • Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting

    Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus

    Daniel J Wallace1, Rosalind Ramsey-Goldman2, Anca D. Askanase3, Susan Manzi4, Joseph Ahearn5, Richard Furie6, Arthur Weinstein7, Chaim Putterman8, Elena Massarotti9, Christopher Collins10, Kenneth Kalunian11, Cristina Arriens12, Stuart L. Silverman13, Smitha Reddy14, Puja Chitkara15, Claudia Ibarra16, Derren Barken17, Roberta Alexander18, John Conklin19 and Thierry Dervieux20, 1Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 2FSM, Northwestern University, Chicago, IL, 3Medicine, Rheumatology, Columbia University Medical Center, New York, NY, 4Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, 5Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, 6North Shore University Hospital, Great Neck, NY, 7Rheumatology Section, Washington Hospital Center, Washington, DC, 8Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 9Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, 10MedStar Washington Hospital Center, Washington, DC, 11Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, 12Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Cedars, Beverly Hills, CA, 14Arthritis Care and Research Center, Inc., Poway, CA, 15Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, 16Clinical Laboratory, Exagen Diagnostics, Vista, CA, 17Exagen Diagnostics, Vista, CA, 18Research & Development, Exagen Diagnostics, Vista, CA, 191261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 20Research and Development, Exagen Diagnostics, Vista, CA

    Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…
  • Abstract Number: 2948 • 2015 ACR/ARHP Annual Meeting

    How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE

    Marta Mosca1, Zahi Touma2, Karen H. Costenbader3, Bimba F. Hoyer4, Chiara Tani1, Alexander Fine5, Sara Tedeschi3, Jorge Medina-Rosas6, Valentina Lorenzoni7, Gian Domenico Sebastiani8, Thomas Dorner9 and on behalf of the SLE Classification Criteria Steering committee, 1University of Pisa, Pisa, Italy, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, 5Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 6University of Toronto, Toronto, ON, Canada, 7SSSUP, Pisa, Italy, 8Osp. San Camillo, Roma, Italy, 9Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine, Berlin, Germany

    Background/Purpose: SLE onset may be insidious with clinically evident disease developing over years. Current SLE classification criteria may not classify patients with early SLE well.…
  • Abstract Number: 769 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus

    Kunihiro Ichinose1, Takeshi Ushigusa2, Masataka Umeda1, Tomohiro Koga2, Atsushi Kawakami2 and Shuntaro Sato3, 1Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan

    Evaluation of Soluble alpha-Klotho in Neuropsychiatric Systemic Lupus ErythematosusABSTRACTBackground/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in SLE that presents a variety of…
  • Abstract Number: 781 • 2015 ACR/ARHP Annual Meeting

    Anti-Nucleosome Antibodies Versus Anti-DNA Antibodies in the Diagnosis and Monitoring of Activity of Systemic Lupus Erytematosus

    Helena Borrell Paños1, Javier Narváez2, Jordi Bas3, Eulàlia Armengol1, Maria Aparicio1, Maria Pascual1, Mercè López de Recalde1 and Joan Miquel Nolla1, 1Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Immunology Department. Hospital Universitari de Bellvitge, Barcelona, Spain

    Background/Purpose: Recently, the study of anti-nucleosome antibodies (ANUCs) has been suggested that they may be useful in the diagnosis of systemic lupus erythematosus (SLE) and in…
  • Abstract Number: 1924 • 2014 ACR/ARHP Annual Meeting

    Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus

    Rosalind Ramsey-Goldman1, Richard Furie2, Chaim Putterman3, Anka Askanase4, Jill P. Buyon5, Kenneth Kalunian6, W. Winn Chatham7, E Massarotti8, Kyriakos A. Kirou9, A. Weinstein10, Puja Chitkara11, Susan Manzi12, Joe Ahearn13, Leilani Wolover14, John Conklin15, Tyler O'Malley14, Claudia Ibarra15, Derren Barken16 and Thierry Dervieux17, 1FSM-300, Northwestern University, Chicago, IL, 2Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, 3The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 4Department of Medicine Rhemuatology, Colombia University, New York, NY, 5Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 6UCSD School of Medicine, La Jolla, CA, 7University of Alabama at Birmingham, Birmingham, AL, 8Brigham and Women's Hospital, Boston, MA, 9Hospital for Special Surgery, New York, NY, 10Washington Hospital Center, Washington, DC, 11Internal Medicine, Sharp Memorial Hospital, San Diego, CA, 12Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 13Internal Medicine, West Penn Allegheny Health System, Pittsburgh, PA, 14Research and Development, Exagen Diagnostics, Inc., Vista, CA, 151261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, 16Exagen Diagnostics, Inc., Vista, CA, 17rd, Exagen Diagnostics, Inc., Vista, CA

    Background/Purpose: Elevated levels of cell bound complement activation products (CBCAPS) have been established as valuable biomarkers in the diagnosis of Systemic Lupus Erythematosus (SLE). In…
  • Abstract Number: 1575 • 2013 ACR/ARHP Annual Meeting

    Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus

    Petra Budde1, Angelika Lueking1, Stefan Vordenbäumen2, Heike Göhler1, Martin Gamer1, Klaus Marquardt1, Anna Telaar1, Daniel Chamrad1, Carmen Theek1, Peter Schulz-Knappe1 and Matthias Schneider2, 1Protagen AG, Dortmund, Germany, 2Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

    Background/Purpose: Diagnosis of systemic lupus erythematosus (SLE) is based on a combination of clinical findings and laboratory evidence such as anti-nuclear autoantibodies (ANA), anti-Smith and…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology